245 related articles for article (PubMed ID: 8595411)
1. Intragenic mutations of CDKN2B and CDKN2A in primary human esophageal cancers.
Suzuki H; Zhou X; Yin J; Lei J; Jiang HY; Suzuki Y; Chan T; Hannon GJ; Mergner WJ; Abraham JM
Hum Mol Genet; 1995 Oct; 4(10):1883-7. PubMed ID: 8595411
[TBL] [Abstract][Full Text] [Related]
2. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines.
Zhou X; Suzuki H; Shimada Y; Imamura M; Yin J; Jiang HY; Tarmin L; Abraham JM; Meltzer SJ
Genes Chromosomes Cancer; 1995 Aug; 13(4):285-90. PubMed ID: 7547637
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
4. Lack of evidence for mutations or deletions in the CDKN2A/p16 and CDKN2B/p15 genes of Brazilian neuroblastoma patients.
Bassi CL; Martelli L; Cipolotti R; Scrideli CA; Defávery R; Tone LG
Braz J Med Biol Res; 2004 Nov; 37(11):1683-7. PubMed ID: 15517085
[TBL] [Abstract][Full Text] [Related]
5. Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Worsham MJ; Chen KM; Tiwari N; Pals G; Schouten JP; Sethi S; Benninger MS
Arch Otolaryngol Head Neck Surg; 2006 Apr; 132(4):409-15. PubMed ID: 16618910
[TBL] [Abstract][Full Text] [Related]
6. Association of CDKN2A(p16)/CDKN2B(p15) alterations and homozygous chromosome arm 9p deletions in human lung carcinoma.
Hamada K; Kohno T; Kawanishi M; Ohwada S; Yokota J
Genes Chromosomes Cancer; 1998 Jul; 22(3):232-40. PubMed ID: 9624535
[TBL] [Abstract][Full Text] [Related]
7. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
[TBL] [Abstract][Full Text] [Related]
8. Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets.
Walker GJ; Flores JF; Glendening JM; Lin AH; Markl ID; Fountain JW
Genes Chromosomes Cancer; 1998 Jun; 22(2):157-63. PubMed ID: 9598804
[TBL] [Abstract][Full Text] [Related]
9. Infrequent mutations and no methylation of CDKN2A (P16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan.
Lin YW; Chen CH; Huang GT; Lee PH; Wang JT; Chen DS; Lu FJ; Sheu JC
Eur J Cancer; 1998 Oct; 34(11):1789-95. PubMed ID: 9893670
[TBL] [Abstract][Full Text] [Related]
10. Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.
Iolascon A; Giordani L; Moretti A; Tonini GP; Lo Cunsolo C; Mastropietro S; Borriello A; Ragione FD
Pediatr Res; 1998 Jan; 43(1):139-44. PubMed ID: 9432125
[TBL] [Abstract][Full Text] [Related]
11. Aberrant methylation of p16INK4a and deletion of p15INK4b are frequent events in human esophageal cancer in Linxian, China.
Xing EP; Nie Y; Wang LD; Yang GY; Yang CS
Carcinogenesis; 1999 Jan; 20(1):77-84. PubMed ID: 9934853
[TBL] [Abstract][Full Text] [Related]
12. High frequency of CDKN2A alterations in esophageal squamous cell carcinoma from a high-risk Chinese population.
Hu N; Wang C; Su H; Li WJ; Emmert-Buck MR; Li G; Roth MJ; Tang ZZ; Lu N; Giffen C; Albert PS; Taylor PR; Goldstein AM
Genes Chromosomes Cancer; 2004 Mar; 39(3):205-16. PubMed ID: 14732922
[TBL] [Abstract][Full Text] [Related]
13. Loss of chromosome arm 9p DNA and analysis of the p16 and p15 cyclin-dependent kinase inhibitor genes in human parathyroid adenomas.
Tahara H; Smith AP; Gaz RD; Arnold A
J Clin Endocrinol Metab; 1996 Oct; 81(10):3663-7. PubMed ID: 8855819
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
15. Homozygous deletions at chromosome 9p21 and mutation analysis of p16 and p15 in microdissected primary non-small cell lung cancers.
Packenham JP; Taylor JA; White CM; Anna CH; Barrett JC; Devereux TR
Clin Cancer Res; 1995 Jul; 1(7):687-90. PubMed ID: 9816033
[TBL] [Abstract][Full Text] [Related]
16. Loss of the cyclin-dependent kinase 4-inhibitor (p16; MTS1) gene is frequent in and highly specific to lymphoid tumors in primary human hematopoietic malignancies.
Ogawa S; Hangaishi A; Miyawaki S; Hirosawa S; Miura Y; Takeyama K; Kamada N; Ohtake S; Uike N; Shimazaki C
Blood; 1995 Aug; 86(4):1548-56. PubMed ID: 7632963
[TBL] [Abstract][Full Text] [Related]
17. Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.
Iolascon A; Giordani L; Moretti A; Basso G; Borriello A; Della Ragione F
Hepatology; 1998 Apr; 27(4):989-95. PubMed ID: 9537438
[TBL] [Abstract][Full Text] [Related]
18. Homozygous deletions but no sequence mutations in coding regions of p15 or p16 in human primary bladder tumors.
Packenham JP; Taylor JA; Anna CH; White CM; Devereux TR
Mol Carcinog; 1995 Nov; 14(3):147-51. PubMed ID: 7576106
[TBL] [Abstract][Full Text] [Related]
19. Cdkn2a, the cyclin-dependent kinase inhibitor encoding p16INK4a and p19ARF, is a candidate for the plasmacytoma susceptibility locus, Pctr1.
Zhang S; Ramsay ES; Mock BA
Proc Natl Acad Sci U S A; 1998 Mar; 95(5):2429-34. PubMed ID: 9482902
[TBL] [Abstract][Full Text] [Related]
20. The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.
Stadler WM; Olopade OI
Urol Res; 1996; 24(4):239-44. PubMed ID: 8873383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
